Sun Pharma declares five-year positive results for ILUMYA (tildrakizumab-asmn)
ILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
ILUMYA
Sun Pharma launches ILUMYA (tildrakizumab) in Japan
It is indicated for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies…
Aim to gain market share, preserve cash, reduce overall debt in times of COVID-19: Dilip Shanghvi
The company's focus is also on supply chain protection and ensuring optimum utilisation of its factories informed the MD of the…
Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA for Middle East &…
ILUMYA (tildrakizumab) is an US FDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with…
Sun Pharma presents insights into clinical use of ILUMYA in moderate-to-severe plaque psoriasis
Reportedly, updated cost analysis reveals ILUMYA is among the most cost-effective first-line treatments for moderate-to-severe…
Sun Pharma presents follow-up data from ILUMYA Phase 3 reSURFACE 1 and 2 trials
Additional data show people with and without metabolic syndrome respond similarly to ILUMYA treatment with comparable, positive…